

Weiterführende Literatur – Konsensus-Statement Angststörungen 2022

- Aliyev NA, Aliyev ZN: Valproate (depakine-chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: randomized, double-blind placebo-controlled study. *Eur Psychiatry* 2008; 23: 109-14
- Baldinger P, Höflich AS, Mitterhauser M, Hahn A, Rami-Mark C, Spies M, Wadsak W, Lanzenberger R, Kasper S: Effects of Silexan on the serotonin-1A receptor and microstructure of the human brain: a randomized, placebo-controlled, double-blind, cross-over study with molecular and structural neuroimaging. *Int J Neuropsychopharmacol* 2014; 18: pyu063
- Bandelow B.: Panik und Agoraphobie. Diagnose, Ursachen, Behandlung. Springer, Wien, New York 2001
- Bandelow B, Sher L, Bunevicius R, Hollander E, Kasper S, Zohar J, Möller HJ, WFSBP Task Force on Mental Disorders in Primary Care, WFSBP Task Force on Anxiety Disorders, OCD and PTSD: Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. *Int J of Psychiatry Clin Pract* 2012; 16: 77-84
- Bandelow B, Michaelis S: Epidemiology of anxiety disorders in the 21st century. *Dialogues Clin Neurosci* 2015; 17: 327-35
- Bandelow B: The myth that psychotherapy is more effective than pharmacotherapy in anxiety disorders. *Eur Neuropsychopharmacol* 2021; 49: 116-8
- Bandelow B, Aden I, Alpers GW, Benecke A, Benecke C, Deckert J, Domschke K, Eckhardt-Henn A, Geiser F, Gerlach AL, Harfst T, Hau S, Hoffmann S, Hoyer J, Hunger-Schoppe C, Kellner M, Köllner V, Kopp IB, Langs G, Liebeck H, Matzat J, Ohly M, Rüdell HP, Rudolf S, Scheufele E, Simon R, Staats H, Ströhle A, Waldherr B, Wedekind D, Werner AM, Wiltink J, Wolters JP, Zwanzger P, Beutel ME: Deutsche S3-Leitlinie Behandlung von Angststörungen, Version 2 (2021)
- Bandelow B, Allgulander C, Baldwin DS, Costa DLDC, Denys D, Dilbaz N, Domschke K, Eriksson E, Fineberg NA, Hättenschwiler J, Hollander E, Kaiya H, Karavaeva T, Kasper S, Katzman M, Kim YK, Inoue T, Lim L, Masdrakis V, Menchón JM, Miguel EC, Möller HJ, Nardi AE, Pallanti S, Perna G, Rujescu D, Starcevic V, Stein DJ, Tsai SJ, Van Ameringen M, Vasileva A, Wang Z, Zohar J: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part I: Anxiety disorders. *World J Biol Psychiatry* 2022; 28: 1-39
- Bartova L, Fugger G, Dold M, Kasper S: Therapieoptionen bei Angsterkrankungen unter Berücksichtigung der Phyto-Psychopharmakotherapie. *J Neurol Neurochir Psychiatr* 2022; 23
- Bartova L, Dold M, Volz HP, Seifritz E, Möller HJ, Kasper S: Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited. *Eur Arch Psychiatry Clin Neurosci* 2022; doi: 10.1007/s00406-022-01390-z; Epub ahead of print
- Bendau A, Petzold MB, Wyka S, Pyrkosch L, Plag J, Ströhle A: Ängste in Zeiten von COVID-19 und anderen Gesundheitskrisen; *Nervenarzt* 2021; 92: 417-25
- COVID-19 Mental Disorders Collaborators: Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic; *Lancet* 2021; 398: 1700-12
- Davidson JR: Pharmacotherapy of social anxiety disorder: what does the evidence tell us? *J Clin Psychiatry* 2006; 67(Suppl. 12): 20-6
- De Lijster JM, Dierckx B, Utens EMWJ, Verhulst FC, Zieldorff C, Dieleman GC, Legerstee JS: The age of onset of anxiety disorders: a meta-analysis. *Can J Psychiatry* 2017; 62: 237-46

- Erfurth A, Sachs G (2020): Angststörungen. In: Steiner M (Hrsg.) Angst. WAS, Bd. 113. Leykam, Graz, Wien
- Fagiolini A, Comandini A, Dell'Osso MC, Kasper S: Rediscovering trazodone for the treatment of major depressive disorder. *CNS Drugs* 2012; 26: 1033-1049
- Gale CK: The treatment of generalised anxiety disorder: a systematic review. *Panminerva Med* 2002; 44: 283-6
- Garakani A, Murrough JW, Freire RC, Thom RP, Larkin K, Buono FD and Iosifescu DV: Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. *Front Psychiatry* 2020; 11: 595584
- Griebel G, Holmes A: 50 years of hurdles and hope in anxiolytic drug discovery. *Nat Rev Drug Discov* 2013; 12: 667-87
- Holt RL, Lydiard RB: Management of treatment-resistant panic disorder. *Psychiatry (Edgmont)* 2007; 4: 48-59
- Kasper S, Volz HP, Dienel A, Schläfke S: Efficacy of Silexan in mixed anxiety-depression - A randomized, placebo-controlled trial. *Eur Neuropsychopharmacol* 2016; 26: 331-40
- Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M; Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University, Antony MM, Bouchard S, Brunet A, Flament M, Grigoriadis S, Mendlowitz S, O'Connor K, Rabheru K, Richter PM, Robichaud M, Walker JR: Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. *BMC Psychiatry* 2014; 14(Suppl. 1): S1. doi: 10.1186/1471-244X-14-S1-S1
- Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen HU: Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. *Int J Methods Psychiatr Res* 2012; 21: 169-84
- Kinrys G, Pollack MH, Simon NM, Worthington JJ, Nardi AE, Versiani M: Valproic acid for the treatment of social anxiety disorder. *Int Clin Psychopharmacol* 2003; 18: 169-72
- Kraus C, Rabl U, Vanicek T, Carlberg L, Popovic A, Spies M, Bartova L, Gryglewski G, Papageorgiou K, Lanzenberger R, Willeit M, Winkler D, Rybakowski JK, Kasper S: Administration of ketamine for unipolar and bipolar depression. *Intl J of Psychiatry Clin Pract* 2017; 21: 2-12
- Lee DJ, Schnitzlein CW, Wolf JP, Vythilingam M, Rasmusson AM, Hoge CW: Psychotherapy versus pharmacotherapy for PTSD: systemic review and meta-analysis to determine first line treatment. *Depress Anxiety* 2016; 33: 792-806
- Möller HJ, Volz HP, Dienel A, Schläfke S, Kasper S: Efficacy of Silexan in subthreshold anxiety: meta-analysis of randomised, placebo-controlled trials. *Eur Arch Psychiatry Clin Neurosci* 2019; 269: 183-93
- Ooi SL, Henderson P, Pak SC: Kava for generalized anxiety disorder: a review of current evidence. *J Altern Complement Med* 2018; 24: 770-80
- Penninx B, Pine DS, Homes EA, Reif A: Anxiety disorders; *Lancet* 2021; 397: 914-27
- Roy-Byrne P: Treatment-refractory anxiety; definition, risk factors, and treatment challenges. *Dialogues Clin Neurosci* 2015; 17: 191-206
- Sachs G, Erfurth A: Obsessive compulsive and related disorders: from the biological basis to a rational pharmacological treatment. *Int J Neuropsychopharmacol* 2018; 21: 59-62
- Sartori SB, Singewald N: Novel pharmacological targets on drug development for the treatment of anxiety and anxiety-related disorders. *Pharmacol Ther* 2019; 204: 107402
- Schiele MA, Herzog K, Kollert L, Böhnlein J, Repple J, Rosenkranz K, Leehr EJ, Ziegler C, Lueken U, Dannlowski U, Pauli P, Arolt V, Zwanzger P, Deckert J, Erfurth A, Domschke K: Affective

temperaments (TEMPS-A) in panic disorder and healthy probands: Genetic modulation by 5-HTT variation. *World J Biol Psychiatry* 2020; 21: 790-6

- Seifritz E, Möller HJ, Volz HP, Müller WE, Hopyan T, Wacker A, Schläfke S, Kasper S: No abuse potential of silexan in healthy recreational drug users: A randomized controlled trial. *Int J Neuropsychopharmacol* 2021; 24: 171-80
- Swoboda MMM, Bartova L, Dremel M, Rabl U, Laggner A, Frey R: The toxicity potential of antidepressants and antipsychotics in relation to other medication and alcohol: A naturalistic and retrospective study. *Front Psychiatry* 2022; 13: 825546
- von Känel R, Kasper S, Bondolfi G, Holsboer-Trachsler E, Hättenschwiler J, Hatzinger M, Imboden C, Heitlinger E, Seifritz E: Therapeutic effects of Silexan on somatic symptoms and physical health in patients with anxiety disorders: A meta-analysis. *Brain Behav* 2021; 11: e01997
- Wittchen HU, Jacobi F: Size and burden of mental disorders in Europe - a critical review and appraisal of 27 studies. *Eur Neuropsychopharmacol* 2005; 15: 357-76
- Zwanzger P, Singewald N, Bandelow B: Pharmacotherapy of anxiety disorders. Guideline-conform treatment and new developments. *Nervenarzt* 2021; 92: 433-40
- Zwanzger P, Diemer J: Angsterkrankungen und Therapieresistenz. *Nervenheilkunde* 2019; 38: 565-9